{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:37Z","timestamp":1790769337218,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":36,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_17","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:36Z","timestamp":1790764476000},"page":"257-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Viral RNA-Targeting Locked Nucleic Acid Gapmers: Design and In Vitro Evaluation"],"prefix":"10.1007","author":[{"given":"Shunsuke","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Itou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Echigoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"3","key":"17_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","volume":"27","author":"RM Meganck","year":"2021","unstructured":"Meganck RM, Baric RS (2021) Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med 27(3):401\u2013410","journal-title":"Nat Med"},{"key":"17_CR2","unstructured":"WHO (2025) Prioritizing diseases for research and development in emergency contexts. https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts. Accessed 3 Dec 2025"},{"key":"17_CR3","unstructured":"WHO (2025) WHO R&D blueprint for epidemics. https:\/\/www.who.int\/teams\/blueprint\/who-r-and-d-blueprint-for-epidemics. Accessed 3 Dec 2025"},{"key":"17_CR4","unstructured":"WHO (2025) Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness. https:\/\/www.who.int\/publications\/m\/item\/pathogens-prioritization-a-scientific-framework-for-epidemic-and-pandemic-research-preparedness. Accessed 3 Dec 2025"},{"key":"17_CR5","unstructured":"WHO (2025) Global Influenza Surveillance and Response System (GISRS). https:\/\/www.who.int\/initiatives\/global-influenza-surveillance-and-response-system. Accessed 3 Dec 2025"},{"key":"17_CR6","unstructured":"WHO (2024) Japanese encephalitis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/japanese-encephalitis. Accessed 3 Dec 2025"},{"issue":"1","key":"17_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s44259-025-00125-z","volume":"3","author":"DZH Aw","year":"2025","unstructured":"Aw DZH, Zhang DX, Vignuzzi M (2025) Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. NPJ Antimicrob Resist 3(1):54. https:\/\/doi.org\/10.1038\/s44259-025-00125-z","journal-title":"NPJ Antimicrob Resist"},{"issue":"10","key":"17_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19(10):673\u2013694. https:\/\/doi.org\/10.1038\/s41573-020-0075-7","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"17_CR9","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","volume":"25","author":"XH Liang","year":"2017","unstructured":"Liang XH, Sun H, Nichols JG, Crooke ST (2017) RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther 25(9):2075\u20132092. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.002","journal-title":"Mol Ther"},{"issue":"1","key":"17_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75(1):285\u2013288. https:\/\/doi.org\/10.1073\/pnas.75.1.285","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"17_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75(1):280\u2013284. https:\/\/doi.org\/10.1073\/pnas.75.1.280","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"17_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/nat.2022.0054","volume":"33","author":"H Takakusa","year":"2023","unstructured":"Takakusa H et al. (2023) Drug metabolism and pharmacokinetics of antisense oligonucleotide therapeutics: typical profiles, evaluation approaches, and points to consider compared with small molecule drugs. Nucleic Acid Ther 33(2):83\u201394. https:\/\/doi.org\/10.1089\/nat.2022.0054","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"17_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu M et al. (2025) Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther 10(1):73. https:\/\/doi.org\/10.1038\/s41392-024-02112-8","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"17_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14737140.2025.2482721","volume":"25","author":"A Bidikian","year":"2025","unstructured":"Bidikian A et al. (2025) Imetelstat in myeloid malignancies: current data and future directions. Expert Rev Anticancer Ther 25(5):517\u2013528. https:\/\/doi.org\/10.1080\/14737140.2025.2482721","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"17_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40265-025-02166-0","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed YY (2025) Olezarsen: first approval. Drugs 85(4):571\u2013576. https:\/\/doi.org\/10.1007\/s40265-025-02166-0","journal-title":"Drugs"},{"issue":"2","key":"17_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-025-02257-y","volume":"86","author":"YY Syed","year":"2026","unstructured":"Syed YY (2026) Donidalorsen: first approval. Drugs 86(2):243\u2013248. https:\/\/doi.org\/10.1007\/s40265-025-02257-y","journal-title":"Drugs"},{"key":"17_CR17","first-page":"53","volume":"49","author":"J Louten","year":"2016","unstructured":"Louten J (2016) Virus replication. Essent Hum Virol 49:53\u201363.","journal-title":"Essent Hum Virol"},{"issue":"12","key":"17_CR18","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3390\/pharmaceutics13122015","volume":"13","author":"W-Y Tarn","year":"2021","unstructured":"Tarn W-Y, Cheng Y, Ko S-H, Huang L-M (2021) Antisense oligonucleotide-based therapy of viral infections. Pharmaceutics 13(12):2015","journal-title":"Pharmaceutics"},{"issue":"8","key":"17_CR19","doi-asserted-by":"publisher","first-page":"104074","DOI":"10.1016\/j.drudis.2024.104074","volume":"29","author":"J Dai","year":"2024","unstructured":"Dai J et al. (2024) Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities. Drug Discov Today 29(8):104074. https:\/\/doi.org\/10.1016\/j.drudis.2024.104074","journal-title":"Drug Discov Today"},{"issue":"1","key":"17_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bcp.13405","volume":"84","author":"JH Beigel","year":"2018","unstructured":"Beigel JH et al. (2018) Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1\/M2 translation. Br J Clin Pharmacol 84(1):25\u201334. https:\/\/doi.org\/10.1111\/bcp.13405","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"17_CR21","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1128\/aac.03442-14","volume":"58","author":"AE Heald","year":"2014","unstructured":"Heald AE et al. (2014) Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother 58(11):6639\u20136647. https:\/\/doi.org\/10.1128\/aac.03442-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"17_CR22","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","volume":"27","author":"MF Yuen","year":"2021","unstructured":"Yuen MF et al. (2021) Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med 27(10):1725\u20131734. https:\/\/doi.org\/10.1038\/s41591-021-01513-4","journal-title":"Nat Med"},{"issue":"1","key":"17_CR23","doi-asserted-by":"publisher","first-page":"e0090022","DOI":"10.1128\/aac.00900-22","volume":"67","author":"K Han","year":"2023","unstructured":"Han K et al. (2023) Comparison of pharmacokinetics of the GalNAc-conjugated antisense oligonucleotide GSK3389404 in participants with chronic hepatitis B infection across the Asia-Pacific region. Antimicrob Agents Chemother 67(1):e0090022. https:\/\/doi.org\/10.1128\/aac.00900-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"17_CR24","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/cts.13531","volume":"16","author":"TT Cheung","year":"2023","unstructured":"Cheung TT et al. (2023) A single ascending dose study of single-stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers. Clin Transl Sci 16(7):1272\u20131282. https:\/\/doi.org\/10.1111\/cts.13531","journal-title":"Clin Transl Sci"},{"issue":"6","key":"17_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/v14061193","volume":"14","author":"A Vaillant","year":"2022","unstructured":"Vaillant A (2022) Targeting subviral particles: a critical step in achieving HBV Functional cure but where are we with current agents in clinical development?. Viruses 14(6):1193. https:\/\/doi.org\/10.3390\/v14061193","journal-title":"Viruses"},{"issue":"24","key":"17_CR26","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","volume":"394","author":"J Hou","year":"2026","unstructured":"Hou J, et al. (2026) Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N Engl J Med 394(24):2395\u20132406. https:\/\/doi.org\/10.1056\/NEJMoa2515131 PMID: 42206582","journal-title":"N Engl J Med"},{"issue":"1","key":"17_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jhep.2005.09.009","volume":"44","author":"JG McHutchison","year":"2006","unstructured":"McHutchison JG et al. (2006) A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 44(1):88\u201396. https:\/\/doi.org\/10.1016\/j.jhep.2005.09.009","journal-title":"J Hepatol"},{"key":"17_CR28","unstructured":"Sarepta Therapeutics (2006) AVI BioPharma announces positive clinical trial results delivering NEUGENE antisense drugs to the central nervous system. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/avi-biopharma-announces-positive-clinical-trial-results . Accessed 12 Dec 2025"},{"issue":"3","key":"17_CR29","first-page":"67","volume":"1","author":"S-K Kim","year":"2015","unstructured":"Kim S-K et al. (2015) Bridged nucleic acids (BNAs) as molecular tools. J Biochem Mol Biol Res 1(3):67\u201371","journal-title":"J Biochem Mol Biol Res"},{"issue":"1","key":"17_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","volume":"23","author":"PH Hagedorn","year":"2018","unstructured":"Hagedorn PH et al. (2018) Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov Today 23(1):101\u2013114. https:\/\/doi.org\/10.1016\/j.drudis.2017.09.018","journal-title":"Drug Discov Today"},{"key":"17_CR31","unstructured":"Aligos Therapeutics (2022) Aligos discontinues development of its antisense oligonucleotide drug candidate ALG-020572 in subjects with chronic hepatitis B and pivots internal strategic emphasis to its small molecule portfolio. https:\/\/investor.aligos.com\/news-releases\/news-release-details\/aligos-discontinues-development-its-antisense-oligonucleotide. Accessed 3 Dec 2025"},{"issue":"1","key":"17_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32216-0","volume":"13","author":"C Zhu","year":"2022","unstructured":"Zhu C et al. (2022) An intranasal ASO therapeutic targeting SARS-CoV-2. Nat Commun 13(1):4503.\u2009https:\/\/doi.org\/10.1038\/s41467-022-32216-0","journal-title":"Nat Commun"},{"issue":"9","key":"17_CR33","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/s41591-022-01908-x","volume":"28","author":"RJ Hagey","year":"2022","unstructured":"Hagey RJ et al. (2022) Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2. Nat Med 28(9):1944\u20131955. https:\/\/doi.org\/10.1038\/s41591-022-01908-x","journal-title":"Nat Med"},{"key":"17_CR34","doi-asserted-by":"publisher","first-page":"105992","DOI":"10.1016\/j.antiviral.2024.105992","volume":"230","author":"M Yamasaki","year":"2024","unstructured":"Yamasaki M et al. (2024) Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA. Antiviral Res 230:105992. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105992","journal-title":"Antiviral Res"},{"key":"17_CR35","doi-asserted-by":"publisher","unstructured":"Okamoto S et al (2023) Antiviral efficacy of RNase H-dependent gapmer antisense oligonucleotides against Japanese encephalitis virus. Int J Mol Sci 24(19):14846. https:\/\/doi.org\/10.3390\/ijms241914846","DOI":"10.3390\/ijms241914846"},{"issue":"suppl_2","key":"17_CR36","doi-asserted-by":"publisher","first-page":"W70","DOI":"10.1093\/nar\/gkn188","volume":"36","author":"AR Gruber","year":"2008","unstructured":"Gruber AR et al. (2008) The Vienna RNA websuite. Nucleic Acids Res 36(suppl_2):W70\u2013W74","journal-title":"Nucleic Acids Res"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:28Z","timestamp":1790766148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":36,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_17","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}